A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006703/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to evaluate the long-term safety and tolerability of SHP465 at
6.25 milligram (mg) in children aged 4 to 12 years diagnosed with
Attention-Deficit/Hyperactivity Disorder (ADHD).
提供机构：
Vivli
创建时间：
2021-02-18
